Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1

Bibliography

• World Health Organization. Towards universal access: Scaling up the priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: World Health Organization: Progress Report 2010. Available from: htpp://www.who.int/hiv/pub/2010progressreport/summary.pdf [Accessed 5th December 2010]
   Google Scholar
• Peeters M, Toure-Kane C, Nkengasong J. Genetic diversity of HIV in Africa: impact on diagnosis, vaccine development and trials. AIDS 2003;17:2547-60
   PubMed Web of Science ®Google Scholar
• Butler IF, Pandrea I, Apetrei C. HIV genetic diversity: biological and public health consequences. Curr HIV Res 2007;5:23-45
   PubMed Web of Science ®Google Scholar
• Mauclere P, Loussert-Ajaka I, Damond F, Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS 1997;11:445-53
   PubMed Web of Science ®Google Scholar
• Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antoretroviral treatment and HIV prevention in Cameroon. PLoS One 2009;4:e7702
   PubMedGoogle Scholar
• Bannister WP, Ruiz L, Loveday C, HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 2006;11:707-15
   PubMed Web of Science ®Google Scholar
• Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 Non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008;10:212-23
   PubMed Web of Science ®Google Scholar
• Tebit DM, Nankya I, Arts EJ, Gao Y. HIV diversity, recombination and disease progression: how does fitness ‘fit’ into the puzzle? AIDS Rev 2007;9:75-87
   PubMed Web of Science ®Google Scholar
• Baeten JM, Chohan B, Lavreys L, HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007;195:1177-80
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR. HIV-1 subtype as a determinant of disease progression. J Infect Dis 2008;197:638-9
   PubMed Web of Science ®Google Scholar
• McBurney SP, Ross TM. Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 2008;7:1405-17
   PubMed Web of Science ®Google Scholar
• Cafaro A, Macchia I, Maggiorella MT, Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv Exp Med Biol 2009;655:189-242
   PubMed Web of Science ®Google Scholar
• Peeters M, Aghokeng AF, Delaporte E. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin Microbiol Infect 2010;16:1525-31
   PubMed Web of Science ®Google Scholar
• Gao F, Chen Y, Levy DN, Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J Virol 2004;78:2426-33
   PubMed Web of Science ®Google Scholar
• Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA 2004;101:4204-9
   PubMed Web of Science ®Google Scholar
• Ramirez BC, Simon-Loriere E, Galetto R, Negroni M. Implications of recombination for HIV diversity. Virus Res 2008;134:64-73
   PubMed Web of Science ®Google Scholar
• Keele BF, Van Heuverswyn F, Li Y, Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006;313:523-6
   PubMed Web of Science ®Google Scholar
• Van Heuverswyn F, Li Y, Neel C, Human immunodeficiency viruses: SIV infection in wild gorillas. Nature 2006;444:164
   PubMed Web of Science ®Google Scholar
• Hirsch VM, Olmsted RA, Murphey-Corb M, An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989;339:389-92
   PubMed Web of Science ®Google Scholar
• Robertson DL, Anderson JP, Bradac JA, HIV-1 nomenclature proposal. Science 2000;288:55-6
   PubMed Web of Science ®Google Scholar
• Peeters M, Sharp P. The genetic diversity of HIV-1: the moving target. AIDS 2000;14:S129-40
   PubMed Web of Science ®Google Scholar
• Archer J, Robertson DL. Understanding the diversification of HIV-1 groups M and O. AIDS 2007;21:1693-700
   PubMed Web of Science ®Google Scholar
• Plantier JC, Leoz M, Dickerson JE, A new human immunodeficiency virus derived from gorillas. Nat Med 2009;15:871-2
   PubMed Web of Science ®Google Scholar
• Vallari A, Holzmayer V, Harris B, Confirmation of Putative HIV-1 Group P in Cameroon. J Virol 2010;85:1403-7
   PubMed Web of Science ®Google Scholar
• Los Alamos National Laboratory. HIV Sequence Database. Available from: http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html [Accessed 4th December 2010]
   Google Scholar
• Vidal N, Bazepeo SE, Mulanga C, Genetic characterization of eight full-length HIV type 1 genomes from the Democratic Republic of Congo (DRC) reveal a new subsubtype, A5, in the A radiation that predominates in the recombinant structure of CRF26_A5U. AIDS Res Hum Retroviruses 2009;25:823-32
   PubMed Web of Science ®Google Scholar
• Djoko CF, Rimoin AW, Vidal N, High HIV Type 1 Group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, DRC. AIDS Res Hum Retroviruses 2011;27:323-9
   Google Scholar
• Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006;20:W13-23
   PubMed Web of Science ®Google Scholar
• Wensing AM, van de Vijver DA, Angarano G, Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66
   PubMed Web of Science ®Google Scholar
• Sagir A, Oette M, Kaiser R, Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007;60:843-8
   PubMed Web of Science ®Google Scholar
• Yerly S, von Wyl V, Ledergerber B, Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007;21:2223-9
   PubMed Web of Science ®Google Scholar
• Holguin A, Pena MJ, Troncoso F, Soriano V. Introduction of non-B subtypes among Spaniards newly diagnosed with HIV type 1 in the Canary Islands. AIDS Res Hum Retroviruses 2007;23:498-502
   PubMed Web of Science ®Google Scholar
• Chaix ML, Descamps D, Wirden M, Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009;23:717-24
   PubMed Web of Science ®Google Scholar
• Fox J, Castro H, Kaye S, Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS 2010;24:2397-401
   PubMed Web of Science ®Google Scholar
• Lai A, Riva C, Marconi A, Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades. HIV Med 2010;11:593-602
   PubMed Web of Science ®Google Scholar
• Saldanha J. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J Clin Virol 2001;20:7-13
   PubMed Web of Science ®Google Scholar
• Van Gemen B, Kievits T, Nara P, Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993;7:S107-10
   PubMed Web of Science ®Google Scholar
• Mulder J, McKinney N, Christopherson C, Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300
   PubMed Web of Science ®Google Scholar
• Pachl C, Todd JA, Kern DG, Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J Acquir Immune Defic Syndr 1995;8:446-54
   Web of Science ®Google Scholar
• Coste J, Montes B, Reyes J, Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol 1996;50:293-302
   PubMed Web of Science ®Google Scholar
• Revets H, Marissens D, de Wit S, Comparative evaluation of NASBA HIV-1 RNA QT, Amplicor-HIV Monitor, and Quantiplex HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 in plasma. J Clin Microbiol 1996;34:1058-64
   PubMed Web of Science ®Google Scholar
• Michael NL, Herman SA, Kwok S, Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtype. J Clin Microbiol 1999;37:110-16
   PubMedGoogle Scholar
• Chew CB, Herring BL, Zheng F, Comparison of three commercial assays for the quantification of HIV-1 RNA in plasma from individuals infected with different HIV-1 subtypes. J Clin Virol 1999;14:87-94
   PubMed Web of Science ®Google Scholar
• Erice A, Brambilla D, Bremer J, Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000;38:2837-45
   PubMed Web of Science ®Google Scholar
• Brambilla DJ, Granger S, Jennings C, Bremer JW. Multisite comparison of reproducibility and recovery from the standard and ultrasensitive Roche AMPLICOR HIV-1 MONITOR assays. J Clin Microbiol 2001;39:1121-3
   PubMed Web of Science ®Google Scholar
• Holzl G, Stocher M, Leb V, Entirely automated quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma by using the ultrasensitive COBAS AMPLICOR HIV-1 monitor test and RNA purification on the MagNA pure LC instrument. J Clin Microbiol 2003;41:1248-51
   PubMed Web of Science ®Google Scholar
• Peter JB, Sevall-Sanders J. Molecular-based methods for quantifying HIV viral load. AIDS Patient Care STDS 2004;18:75-9
   PubMed Web of Science ®Google Scholar
• Nkengasong JN, Kalou M, Maurice C, Comparison of Nuclisens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Cote d'Ivoire. J Clin Microbiol 1998;36:2495-8
   PubMed Web of Science ®Google Scholar
• Triques K, Coste J, Perret JL, Efficiencies of four versions of the Amplicor HIV-1 Monitor test for quantification of different subtypes of human immunodeficiency virus type 1. J Clin Microbiol 1999;37:110-16
   PubMed Web of Science ®Google Scholar
• Burgisser P, Vernazza P, Flepp M, Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. J Acquir Immune Defic Syndr 2000;23:138-44
   PubMed Web of Science ®Google Scholar
• Jenny-Avital ER, Beatrice ST. Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin Infect Dis 2001;32:1227-30
   PubMed Web of Science ®Google Scholar
• Amendola A, Bordi L, Angeletti C, Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). J Acquir Immune Defic Syndr 2002;31:488-94
   PubMed Web of Science ®Google Scholar
• Hoesley CJ, Allen SA, Raper JL, Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C. Clin Infect Dis 2002;35:323-5
   PubMed Web of Science ®Google Scholar
• Antunes R, Figueiredo S, Bartolo I, Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J Clin Microbiol 2003;41:3361-7
   PubMed Web of Science ®Google Scholar
• Amendola A, Bordi L, Angeletti C, Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02). J Clin Microbiol 2004;42:811-15
   PubMed Web of Science ®Google Scholar
• Gottesman BS, Grosman Z, Lorber M, Measurement of HIV RNA in patients infected by subtype C by assays optimized for subtype B results in an underestimation of the viral load. J Med Virol 2004;73:167-71
   PubMed Web of Science ®Google Scholar
• Swanson P, de Mendoza C, Joshi Y, Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 2005;43:3860-8
   PubMed Web of Science ®Google Scholar
• Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY) 1992;10:413-17
   PubMedGoogle Scholar
• Wittek M, Sturmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev Mol Diagn 2007;7:237-46
   PubMed Web of Science ®Google Scholar
• Rouet F, Menan H, Viljoen J, In-house HIV-1 RNA real-time reverse transcription PCR assays: principle, available tests and usefulness in developing countries. Expert Rev Mol Diagn 2008;8:635-50
   PubMed Web of Science ®Google Scholar
• Rouet F, Ekouevi DK, Chaix ML, Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005;43:2709-17
   PubMed Web of Science ®Google Scholar
• Rouet F, Chaix ML, Nerrienet E, Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction. J Acquir Immune Defic Syndr 2007;45:380-8
   PubMed Web of Science ®Google Scholar
• Jagodzinski LL, Wiggins DL, McManis JL, Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol 2000;38:1247-9
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DJ. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995;346:1085-7
   PubMed Web of Science ®Google Scholar
• Scott LE, Galpin JS, Glencross DK. Multiple method comparison: statistical model using percentage similarity. Cytometry B Clin Cytom 2003;54:46-53
   PubMedGoogle Scholar
• Foulongne V, Montes B, Didelot Rousseau MN, Segondy M. Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J Clin Microbiol 2006;44:2963-6
   PubMed Web of Science ®Google Scholar
• Garcia-Diaz A, Clewley GS, Booth CL, Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type I (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol 2006;44:1788-91
   PubMed Web of Science ®Google Scholar
• Swanson P, Huang S, Abravaya K, Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2006;141:49-57
   PubMed Web of Science ®Google Scholar
• Swanson P, Holzmayer V, Huang S, Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from London: comparision to VERSANT HIV-1 RNA 3.0, AMPLICOR HIV-1 MONITOR v1.5 and LCx HIV RNA quantitative assays. J Virol Methods 2006;137:184-92
   PubMed Web of Science ®Google Scholar
• Gueudin M, Plantier JC, Lemee V, Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr 2007;44:500-5
   PubMed Web of Science ®Google Scholar
• Swanson P, Huang S, Abravaya K, Evaluation of the performance acrosse the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. J Virol Methods 2007;141:49-57
   PubMed Web of Science ®Google Scholar
• Braun P, Ehret R, Wiesmann F, Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin Chem Lab Med 2007;45:93-9
   PubMed Web of Science ®Google Scholar
• Schutten M, Peters D, Back NKT, Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2007;45:1712-17
   PubMed Web of Science ®Google Scholar
• Tang N, Huang SH, Salituro J, A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007;146:236-45
   PubMed Web of Science ®Google Scholar
• Schutten M, Fries E, Burghoorn-Maas C, Niesters HG. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol 2007;40:99-104
   PubMed Web of Science ®Google Scholar
• Xu S, Song A, Li X, Performance of the Abbott RealTime HIV-1 assay for quantification of HIV-1 clades prevalent in China. J Clin Virol 2008;41:305-9
   PubMed Web of Science ®Google Scholar
• Sloma CR, Germer JJ, Gerads TM, Comparison of the Abbott RealTime Human Immunodeficiency Virus Type 1 (HIV-1) Assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test: workflow, reliability, and direct costs. J Clin Microbiol 2009;47:889-95
   PubMed Web of Science ®Google Scholar
• Crump JA, Scott LE, Msuya E, Evaluation of the Abbott m2000rt RealTime (TM) HIV-1 assay with manual sample preparation compared with the ROCHE COBAS (R) AmpliPrep (TM)/AMPLICOR (TM) HIV-1 MONITOR (R) v1.5 using specimens from East Africa. J Virol Methods 2009;162:218-22
   PubMed Web of Science ®Google Scholar
• Wirden M, Tubiana R, Marguet F, Impact of discrepancies between the Abbott RealTime and Cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 2009;47:1543-5
   PubMed Web of Science ®Google Scholar
• Scott EL, Noble LD, Moloi J, Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J Clin Microbiol 2009;47:2209-17
   PubMed Web of Science ®Google Scholar
• Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott Investigational use only RealTime HIV-1 assay and comparison to the Roche Amplicor HIV-1 Monitor test, version 1.5. J Mol Diagn 2009;11:347-54
   PubMed Web of Science ®Google Scholar
• Choi JY, Kim EJ, Rho HJ, Evaluation of the NucliSens EasyQ HIV-1 v1.1 and RealTime HIV-1 kits for quantitation of HIV-1 RNA in plasma. J Virol Methods 2009;161:7-11
   PubMed Web of Science ®Google Scholar
• Babady NE, Germer JJ, Yao JDC. Results of the Abbott RealTime HIV-1 Assay for Specimens Yielding ‘Target Not Detected’ Results by the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test. J Clin Microbiol 2010;48:969-71
   PubMed Web of Science ®Google Scholar
• Katsoulidou A, Petrodaskalaki M, Sypsa V, Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays--LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J Virol Methods 2006;131:168-74
   PubMed Web of Science ®Google Scholar
• Gomes P, Palma AC, Cabanas J, Comparison of the COBAS TAQMAN (TM) HIV-1HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. J Virol Methods 2006;135:223-8
   PubMed Web of Science ®Google Scholar
• Perrin L, Pawlotsky JM, Bouvier Alias M, Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol 2006;44:4371-5
   PubMed Web of Science ®Google Scholar
• Schumacher W, Frick E, Kauselmann M, Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2007;38:304-12
   PubMed Web of Science ®Google Scholar
• Damond F, Roquebert B, Benard A, Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007;45:3436-8
   PubMed Web of Science ®Google Scholar
• Oliver AR, Pereira SF, Clark DA. A comparative evaluation of the automated Roche Taqman realtime quantitative HIV 1 RNA PCR assay with the Roche Amplicor v1.5 conventional PCR assay. J Clin Microbiol 2007;45:3616-19
   PubMed Web of Science ®Google Scholar
• Holguin A, Lopez M, Molinero M, Soriano V. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol 2008;46:2918-23
   PubMed Web of Science ®Google Scholar
• Korn K, Weissbrich B, Henke-Gendo C, Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009;47:1238-40
   PubMed Web of Science ®Google Scholar
• Scott L, Carmona S, Stevens W. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol 2009;47:3400-2
   PubMed Web of Science ®Google Scholar
• Taylor N, Schmid I, Egle A, Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antivir Ther 2009;14:1189-93
   PubMed Web of Science ®Google Scholar
• Sizmann D, Glaubitz J, Simon CO, Improved HIV-1 RNA quantitation by COBAS (R) AmpliPrep/COBAS (R) TaqMan (R) HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010;49:41-6
   PubMed Web of Science ®Google Scholar
• Pas S, Rossen JWA, Schoener D, Performance evaluation of the new roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA. J Clin Microbiol 2010;48:1195-200
   PubMed Web of Science ®Google Scholar
• De Bel A, Marissens D, Debaisieux L, Correction of underquantification of human immunodeficiency virus type 1 load with the second version of the Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol 2010;48:1337-42
   PubMed Web of Science ®Google Scholar
• Damond F, Avettand-Fenoel V, Collin G, Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 2010;48:1413-16
   PubMed Web of Science ®Google Scholar
• Janse van Rensburg E, Tait K, Watt A, Schall R. Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test on the TaqMan 48 analyzer (CAP/CTM-48 v2) and the Abbott Real Time (RT) HIV-1 assay. J Clin Microbiol 2010;49:377-9
   PubMed Web of Science ®Google Scholar
• Bourlet T, Signori-Schmuck A, Roche L, HIV-1 viral load comparison between four commercial real-time assays. J Clin Microbiol 2010;49:292-7
   PubMed Web of Science ®Google Scholar
• de Mendoza C, Koppelman M, Montes B, Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods 2005;127:54-9
   PubMed Web of Science ®Google Scholar
• Stevens W, Wiggill T, Horsfield P, Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. J Virol Methods 2005;124:105-10
   PubMed Web of Science ®Google Scholar
• Yao J, Liu Z, Ko LS, Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods 2005;129:40-6
   PubMed Web of Science ®Google Scholar
• McClernon DR, Vavro C, St Clair M. Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1. J Clin Microbiol 2006;44:2280-2
   PubMed Web of Science ®Google Scholar
• Gottesman BS, Grossman Z, Lorber M, Comparative performance of the amplicor HIV-1 monitor assay versus NucliSens EasyQ in HIV subtype C-infected patients. J Med Virol 2006;78:883-7
   PubMed Web of Science ®Google Scholar
• Lam HY, Chen JH, Wong KH, Evaluation of Nuclisens EasyQ HIV-1 assay for quantification of HIV-1 subtypes prevalent in South-east Asia. J Clin Virol 2007;38:39-43
   PubMed Web of Science ®Google Scholar
• Wang YC, Song AJ, Xu SH, Impact of HIV-1 genetic diversity in China on the measurement of viral load. J Med Virol 2008;80:1-8
   PubMed Web of Science ®Google Scholar
• Ruelle J, Jnaoui K, Lefevre I, Comparative evaluaiton of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009;44:297-301
   PubMed Web of Science ®Google Scholar
• Troppan KT, Stelzl E, Violan D, Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol 2009;46:69-74
   PubMed Web of Science ®Google Scholar
• Steegen K, Luchters S, De Cabooter N, Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J Virol Methods 2007;146:178-87
   PubMed Web of Science ®Google Scholar
• Rouet F, Foulongne V, Viljoen J, Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 Monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods 2010;163:253-7
   PubMed Web of Science ®Google Scholar
• Khodakov DA, Zakharova NV, Gryadunov DA, An oligonucleotide microarray for multiplex real-time PCR identification of HIV-1, HBV, and HCV. Biotechniques 2008;44:241-8
   PubMed Web of Science ®Google Scholar
• Stevens WS, Marshall TM. Challenges in implementing HIV load testing in South Africa. J Infect Dis 2010;201:S78-84
   PubMed Web of Science ®Google Scholar
• Ho DD, Neumann AU, Perelson AS, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6
   PubMed Web of Science ®Google Scholar
• O'Brien WA, Hartigan PM, Martin D, Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31
   PubMed Web of Science ®Google Scholar
• Mellors JW, Munoz A, Giorgi JV, Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54
   PubMed Web of Science ®Google Scholar
• Perelson AS, Essunger P, Cao Y. Decay characteristics of HIV-1-infected compartements during combination therapy. Nature 1997;387:188-91
   PubMed Web of Science ®Google Scholar
• Shearer WT, Quinn TC, LaRussa P, Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997;336:1337-42
   PubMed Web of Science ®Google Scholar
• Palumbo PE, Raskino C, Fiscus S, Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children. JAMA 1998;279:756-61
   PubMed Web of Science ®Google Scholar
• Mellors JW, Margolick JB, Phair JP, Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 2007;297:2349-50
   PubMed Web of Science ®Google Scholar
• Hammer SM, Katzenstein DA, Hughes MD, A trial comparing nucleoside monotherapy with combination therapy in HIV-1 infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trial Groups Study 175 Team. N Engl J Med 1996;335:1081-90
   PubMed Web of Science ®Google Scholar
• Bogaards JA, Goudsmit J. Meeting the immense need for HAART in resource-poor settings. J Antimicrob Chemother 2003;52:743-6
   PubMed Web of Science ®Google Scholar
• Burgoyne RW, Tan DHS. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act. J Antimicrob Chemother 2008;61:469-73
   PubMed Web of Science ®Google Scholar
• Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010;85:1-18
   PubMed Web of Science ®Google Scholar
• Kupfer B, Matz B, Daumer M, Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load < 50 copies/ml. J Med Virol 2007;79:1440-5
   PubMed Web of Science ®Google Scholar
• Pasternak A, Adema K, Bakker M, Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 2008;46:2206-11
   PubMed Web of Science ®Google Scholar
• Pasternak A, Jurriaans S, Bakker M, Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009;4:e8490
   PubMed Web of Science ®Google Scholar
• Palumbo P, Kwok S, Waters S, Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants. J Pediatr 1995;126:592-5
   PubMed Web of Science ®Google Scholar
• Rouzioux C, Costagliola D, Burgard M, Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. Am J Epidemiol 1995;142:1330-7
   PubMed Web of Science ®Google Scholar
• Dunn DT, Brandt CD, Krivine A, The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995;9:F7-11
   PubMed Web of Science ®Google Scholar
• Lambert JS, Harris DR, Stiehm ER, Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 2003;34:512-19
   PubMed Web of Science ®Google Scholar
• Blattner WA, Oursler KA, Cleghorn F, Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004;189:1793-801
   PubMed Web of Science ®Google Scholar
• Messou E, Gabillard D, Moh R, Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. Bull World Health Organ 2008;86:435-42
   PubMed Web of Science ®Google Scholar
• Mee P, Fielding K, Charalambous S, Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008;22:1971-7
   PubMed Web of Science ®Google Scholar
• Gupta RK, Hill A, Sawyer AW, Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-17
   PubMed Web of Science ®Google Scholar
• Fiscus SA, Cheng B, Crowe SM, HIV-1 viral load assays for resource-limited settings. PLoS Med 2006;3:e417
   PubMed Web of Science ®Google Scholar
• Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab 2007;53:135-48
   PubMed Web of Science ®Google Scholar
• Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. J Infect Dis 2010;201:S16-26
   PubMed Web of Science ®Google Scholar
• Viljoen J, Gampini S, Danaviah S, Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr 2010;55:290-8
   PubMed Web of Science ®Google Scholar